64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
Clinical trial NCT05633160 · TERMINATED
Trial details
- NCT number
- NCT05633160
- Sponsor
- Clarity Pharmaceuticals Ltd
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-15
- Primary completion
- 2025-04-23
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.